Recursion Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Recursion Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 87% in 3 years, but profit fell: $1,172 less profit per $100 of extra sales. Lower than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-26.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 62% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 0/3Sales grew in 3 of the last 3 years; profit grew in 0 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
−$1,172Sales grew 87% in 3 years, but profit fell: $1,172 less profit per $100 of extra sales.
Lower than 96% of Healthcare companies in United States.
Asset Productivity Ratio
+87% / +110%In 3 years sales changed by +87% while total assets changed by +110%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-40.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 69% of Healthcare companies in United States.
Cash Cushion Ratio
+35%Cash, after subtracting all debt, equals 35% of its market value (net cash).
Higher than 71% of Healthcare companies in United States.
Tangible Assets Ratio
68%Of every $100 the company owns, $68 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 64% of Healthcare companies in United States.
Tangible Net Worth Ratio
58%Of every $100 of net worth, $58 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 51% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Recursion Pharmaceuticals, Inc. made a loss over the last year. Recursion Pharmaceuticals, Inc. owes $0.25 for every $1 it owns. Recursion Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRecursion Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.17The share price is 2.17 times Recursion Pharmaceuticals, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$2.0 BThe total market value of all of Recursion Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$915 MWhat Recursion Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.71Net worth divided by the number of shares. The share price of $3.70 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-56.6%Recursion Pharmaceuticals, Inc. lost 56.6% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
Owes vs Owns
0.25×Recursion Pharmaceuticals, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Dividend yield
NoneRecursion Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+27%Revenue rose 27% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Profit growth
LossRecursion Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-868.3%Recursion Pharmaceuticals, Inc. lost $868 for every $100 of revenue.
Interest cover
Not coveredRecursion Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashRecursion Pharmaceuticals, Inc. held $665 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Recursion Pharmaceuticals, Inc.: $2.0 B ÷ $915 M (30 Jun 2026) = 2.2.
What is Recursion Pharmaceuticals, Inc.'s return on equity?
Recursion Pharmaceuticals, Inc. lost 56.6% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
How much does Recursion Pharmaceuticals, Inc. owe compared with what it owns?
Recursion Pharmaceuticals, Inc. owes $0.25 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Does Recursion Pharmaceuticals, Inc. pay a dividend?
No. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.
Is Recursion Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 27% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.